Trade ImmuCell - ICCC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 4.45 |
| Open* | 4.39 |
| 1-Year Change* | -32.57% |
| Day's Range* | 4.39 - 4.49 |
| 52 wk Range | 4.26-7.84 |
| Average Volume (10 days) | 13.61K |
| Average Volume (3 months) | 365.10K |
| Market Cap | 35.65M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 7.75M |
| Revenue | 16.29M |
| EPS | -0.81 |
| Dividend (Yield %) | N/A |
| Beta | 0.60 |
| Next Earnings Date | Feb 19, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 7, 2023 | 4.45 | 0.03 | 0.68% | 4.42 | 4.49 | 4.42 |
| Dec 6, 2023 | 4.45 | 0.00 | 0.00% | 4.45 | 4.55 | 4.37 |
| Dec 5, 2023 | 4.44 | -0.01 | -0.22% | 4.45 | 4.45 | 4.37 |
| Dec 4, 2023 | 4.47 | 0.03 | 0.68% | 4.44 | 4.47 | 4.44 |
| Dec 1, 2023 | 4.44 | -0.04 | -0.89% | 4.48 | 4.50 | 4.44 |
| Nov 30, 2023 | 4.53 | 0.03 | 0.67% | 4.50 | 4.59 | 4.49 |
| Nov 29, 2023 | 4.63 | -0.06 | -1.28% | 4.69 | 4.71 | 4.59 |
| Nov 28, 2023 | 4.52 | -0.08 | -1.74% | 4.60 | 4.60 | 4.49 |
| Nov 27, 2023 | 4.62 | -0.13 | -2.74% | 4.75 | 4.85 | 4.62 |
| Nov 24, 2023 | 4.60 | -0.05 | -1.08% | 4.65 | 4.74 | 4.55 |
| Nov 22, 2023 | 4.49 | 0.05 | 1.13% | 4.44 | 4.54 | 4.44 |
| Nov 21, 2023 | 4.54 | -0.16 | -3.40% | 4.70 | 4.70 | 4.26 |
| Nov 20, 2023 | 4.61 | 0.01 | 0.22% | 4.60 | 4.70 | 4.55 |
| Nov 17, 2023 | 4.75 | 0.05 | 1.06% | 4.70 | 4.78 | 4.70 |
| Nov 16, 2023 | 4.66 | -0.07 | -1.48% | 4.73 | 4.79 | 4.57 |
| Nov 15, 2023 | 5.01 | -0.01 | -0.20% | 5.02 | 5.22 | 5.00 |
| Nov 14, 2023 | 5.24 | -0.05 | -0.95% | 5.29 | 5.29 | 4.75 |
| Nov 13, 2023 | 5.19 | 0.09 | 1.76% | 5.10 | 5.36 | 5.08 |
| Nov 10, 2023 | 5.18 | -0.12 | -2.26% | 5.30 | 5.38 | 5.17 |
| Nov 9, 2023 | 5.23 | 0.06 | 1.16% | 5.17 | 5.27 | 5.17 |
ImmuCell Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, February 19, 2024 | ||
| Time (UTC) 21:00 | Country US
| Event Q4 2023 ImmuCell Corp Earnings Release Q4 2023 ImmuCell Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 18.568 | 19.243 | 15.3422 | 13.7229 | 10.9863 |
| Revenue | 18.568 | 19.243 | 15.3422 | 13.7229 | 10.9863 |
| Cost of Revenue, Total | 10.9192 | 10.587 | 8.47938 | 6.98315 | 5.79239 |
| Gross Profit | 7.64878 | 8.65593 | 6.86282 | 6.73972 | 5.19391 |
| Total Operating Expense | 20.8669 | 18.9856 | 15.8796 | 14.6768 | 12.4329 |
| Selling/General/Admin. Expenses, Total | 5.45385 | 4.23003 | 3.88855 | 4.00602 | 3.82386 |
| Research & Development | 4.49387 | 4.16852 | 4.35463 | 3.68761 | 3.51662 |
| Operating Income | -2.29895 | 0.25739 | -0.53744 | -0.95391 | -1.44657 |
| Interest Income (Expense), Net Non-Operating | -0.19544 | -0.29555 | -0.29047 | -0.31351 | -0.41348 |
| Other, Net | 0.00091 | 0 | -0.16505 | 0 | |
| Net Income Before Taxes | -2.48613 | -0.06913 | -1.03225 | -1.26741 | -1.86005 |
| Net Income After Taxes | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Net Income Before Extra. Items | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Net Income | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Income Available to Common Excl. Extra. Items | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Income Available to Common Incl. Extra. Items | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Dilution Adjustment | |||||
| Diluted Net Income | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Diluted Weighted Average Shares | 7.74512 | 7.59229 | 7.21333 | 6.81896 | 5.48615 |
| Diluted EPS Excluding Extraordinary Items | -0.32198 | -0.01031 | -0.1417 | -0.19 | -0.42319 |
| Diluted Normalized EPS | -0.3226 | -0.00766 | -0.21411 | -0.19 | -0.50612 |
| Total Extraordinary Items | |||||
| Unusual Expense (Income) | -0.84292 | -0.7 | |||
| Gain (Loss) on Sale of Assets | 0.00733 | -0.03096 | -0.0393 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 3.53268 | 3.44653 | 3.91088 | 4.79603 | 9.86106 |
| Revenue | 3.53268 | 3.44653 | 3.91088 | 4.79603 | 9.86106 |
| Cost of Revenue, Total | 2.48879 | 3.14575 | 2.9187 | 2.94997 | 5.05051 |
| Gross Profit | 1.04389 | 0.30078 | 0.99218 | 1.84606 | 4.81055 |
| Total Operating Expense | 4.83718 | 5.70257 | 5.54463 | 5.41282 | 9.90946 |
| Selling/General/Admin. Expenses, Total | 1.24885 | 1.44645 | 1.57652 | 1.19308 | 2.68425 |
| Research & Development | 1.09954 | 1.11037 | 1.04941 | 1.26976 | 2.1747 |
| Operating Income | -1.3045 | -2.25604 | -1.63375 | -0.61679 | -0.0484 |
| Interest Income (Expense), Net Non-Operating | -0.07377 | -0.04935 | -0.02893 | -0.03442 | -0.13207 |
| Gain (Loss) on Sale of Assets | 0.00008 | -0.00824 | -0.00367 | 0 | 0.011 |
| Other, Net | 0 | 0.00011 | 0 | 0.00091 | |
| Net Income Before Taxes | -1.37819 | -2.31353 | -1.66636 | -0.65121 | -0.16857 |
| Net Income After Taxes | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Net Income Before Extra. Items | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Net Income | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Income Available to Common Excl. Extra. Items | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Income Available to Common Incl. Extra. Items | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Diluted Net Income | -1.37971 | -2.31505 | -1.66787 | -0.65508 | -0.17086 |
| Diluted Weighted Average Shares | 7.74686 | 7.74686 | 7.74689 | 7.74686 | 7.7457 |
| Diluted EPS Excluding Extraordinary Items | -0.1781 | -0.29884 | -0.2153 | -0.08456 | -0.02206 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.17811 | -0.29815 | -0.21499 | -0.08456 | -0.02298 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 13.9948 | 16.2649 | 12.157 | 13.189 | 6.42084 |
| Cash and Short Term Investments | 5.79156 | 10.1855 | 7.94643 | 8.77405 | 2.52105 |
| Cash & Equivalents | 5.79156 | 10.1855 | 6.94994 | 6.29329 | 2.52105 |
| Short Term Investments | 0 | 0.9965 | 2.48075 | ||
| Total Receivables, Net | 1.80078 | 2.72071 | 1.86442 | 1.6777 | 0.9323 |
| Accounts Receivable - Trade, Net | 1.7586 | 2.69423 | 1.7968 | 1.63717 | 0.9323 |
| Total Inventory | 6.03854 | 3.08997 | 2.09251 | 2.51826 | 2.33167 |
| Prepaid Expenses | 0.36388 | 0.26871 | 0.25284 | 0.21823 | 0.63582 |
| Other Current Assets, Total | 0 | 0.0008 | 0.0008 | ||
| Total Assets | 44.8606 | 44.4657 | 40.3496 | 38.6918 | 32.7308 |
| Property/Plant/Equipment, Total - Net | 30.6364 | 28.0027 | 27.9753 | 25.2657 | 26.0275 |
| Goodwill, Net | 0.09556 | 0.09556 | 0.09556 | 0.09556 | 0.09556 |
| Intangibles, Net | 0.05731 | 0.07642 | 0.09552 | 0.11462 | 0.13373 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 0.07663 | 0.02612 | 0.02617 | 0.02688 | 0.05316 |
| Total Current Liabilities | 3.07207 | 2.53447 | 2.21108 | 2.49536 | 2.56501 |
| Payable/Accrued | 1.22066 | ||||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.03945 | 0.81221 | 0.76034 | 1.27479 | 1.34435 |
| Other Current Liabilities, Total | 0.14876 | 0.20122 | 0.13748 | 0.17511 | 0 |
| Total Liabilities | 14.4806 | 11.8888 | 12.0834 | 9.70056 | 10.9865 |
| Total Long Term Debt | 9.19111 | 8.32712 | 8.73715 | 7.14668 | 8.42149 |
| Long Term Debt | 9.19111 | 8.32712 | 8.73715 | 7.14668 | 8.42149 |
| Other Liabilities, Total | 2.21742 | 1.02716 | 1.13517 | 0.05853 | 0 |
| Total Equity | 30.3801 | 32.5769 | 28.2662 | 28.9913 | 21.7443 |
| Common Stock | 0.78142 | 0.78142 | 0.7299 | 0.7299 | 0.56627 |
| Additional Paid-In Capital | 35.9784 | 35.6924 | 31.3721 | 31.1319 | 22.6956 |
| Retained Earnings (Accumulated Deficit) | -6.2325 | -3.73869 | -3.6604 | -2.63829 | -1.3427 |
| Treasury Stock - Common | -0.14723 | -0.15817 | -0.17539 | -0.18834 | -0.20495 |
| Other Equity, Total | 0 | -0.0439 | 0.03016 | ||
| Total Liabilities & Shareholders’ Equity | 44.8606 | 44.4657 | 40.3496 | 38.6918 | 32.7308 |
| Total Common Shares Outstanding | 7.74686 | 7.74186 | 7.21884 | 7.21292 | 5.56896 |
| Property/Plant/Equipment, Total - Gross | 46.512 | 41.996 | 39.6407 | 34.8769 | |
| Accumulated Depreciation, Total | -15.8756 | -13.9933 | -11.6653 | -9.61119 | |
| Accounts Payable | 0.79 | 0.74504 | 0.60235 | 0.57218 | |
| Accrued Expenses | 1.09387 | 0.776 | 0.71091 | 0.47328 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 11.9621 | 10.9455 | 12.2483 | 13.9948 | 16.4331 |
| Cash and Short Term Investments | 1.98946 | 1.45431 | 3.09605 | 5.79156 | 8.82777 |
| Cash & Equivalents | 1.98946 | 1.45431 | 3.09605 | 5.79156 | 8.82777 |
| Short Term Investments | |||||
| Total Receivables, Net | 2.0095 | 1.52199 | 2.14209 | 1.80078 | 1.73512 |
| Accounts Receivable - Trade, Net | 1.86459 | 1.49885 | 2.0903 | 1.7586 | 1.70183 |
| Total Inventory | 7.38566 | 7.53598 | 6.32833 | 6.03854 | 5.31778 |
| Prepaid Expenses | 0.57748 | 0.43324 | 0.68183 | 0.36388 | 0.55243 |
| Other Current Assets, Total | |||||
| Total Assets | 44.545 | 44.0071 | 43.1232 | 44.8606 | 46.4016 |
| Property/Plant/Equipment, Total - Net | 32.3743 | 32.8358 | 30.639 | 30.6364 | 29.7862 |
| Property/Plant/Equipment, Total - Gross | 50.1882 | 49.9952 | 47.1328 | 46.512 | 45.6052 |
| Accumulated Depreciation, Total | -17.8138 | -17.1594 | -16.4937 | -15.8756 | -15.819 |
| Goodwill, Net | 0.09556 | 0.09556 | 0.09556 | 0.09556 | 0.09556 |
| Intangibles, Net | 0.04298 | 0.04776 | 0.05254 | 0.05731 | 0.06209 |
| Other Long Term Assets, Total | 0.07004 | 0.08246 | 0.08778 | 0.07663 | 0.02457 |
| Total Current Liabilities | 3.32797 | 4.19313 | 3.83793 | 3.07207 | 2.715 |
| Accounts Payable | 0.77985 | 0.9184 | 0.79485 | 0.79 | 0.75934 |
| Accrued Expenses | 0.92972 | 1.09283 | 0.84081 | 1.09387 | 0.69158 |
| Notes Payable/Short Term Debt | 0 | 1 | 1 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.41123 | 1.0904 | 1.06423 | 1.03945 | 0.99816 |
| Other Current Liabilities, Total | 0.20718 | 0.0915 | 0.13804 | 0.14876 | 0.26592 |
| Total Liabilities | 18.5315 | 17.15 | 14.9621 | 14.4806 | 14.419 |
| Total Long Term Debt | 10.9047 | 8.64072 | 8.91687 | 9.19111 | 9.47868 |
| Long Term Debt | 10.9047 | 8.64072 | 8.91687 | 9.19111 | 9.47868 |
| Other Liabilities, Total | 4.29882 | 4.31616 | 2.20728 | 2.21742 | 2.22536 |
| Total Equity | 26.0135 | 26.8571 | 28.1611 | 30.3801 | 31.9825 |
| Common Stock | 0.78142 | 0.78142 | 0.78142 | 0.78142 | 0.78142 |
| Additional Paid-In Capital | 36.2466 | 36.1501 | 36.0745 | 35.9784 | 35.913 |
| Retained Earnings (Accumulated Deficit) | -10.8673 | -9.92727 | -8.54755 | -6.2325 | -4.56463 |
| Treasury Stock - Common | -0.14723 | -0.14723 | -0.14723 | -0.14723 | -0.14723 |
| Total Liabilities & Shareholders’ Equity | 44.545 | 44.0071 | 43.1232 | 44.8606 | 46.4016 |
| Total Common Shares Outstanding | 7.74686 | 7.74686 | 7.74686 | 7.74686 | 7.74686 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -2.49381 | -0.07829 | -1.02212 | -1.29559 | -2.32167 |
| Cash From Operating Activities | -1.54387 | 0.95417 | 1.31558 | 0.23351 | -0.3734 |
| Cash From Operating Activities | 2.46848 | 2.44204 | 2.32818 | 2.24832 | 1.50161 |
| Amortization | 0.0191 | 0.0191 | 0.0191 | 0.0191 | 0.0191 |
| Deferred Taxes | 0 | -0.01463 | 0.02468 | 0.46232 | |
| Non-Cash Items | 0.29504 | 0.19383 | -0.52722 | 0.33259 | -0.33742 |
| Cash Taxes Paid | 0.00492 | 0.00511 | 0.00458 | 0.00357 | 0.00422 |
| Cash Interest Paid | 0.33852 | 0.30868 | 0.48141 | 0.42096 | 0.40354 |
| Changes in Working Capital | -1.83269 | -1.62251 | 0.53226 | -1.0956 | 0.30266 |
| Cash From Investing Activities | -3.96427 | -1.59736 | -2.56994 | -3.40336 | -1.79397 |
| Capital Expenditures | -3.97527 | -2.60865 | -4.07254 | -1.39145 | -2.0299 |
| Other Investing Cash Flow Items, Total | 0.011 | 1.01129 | 1.5026 | -2.01191 | 0.23592 |
| Cash From Financing Activities | 1.11424 | 3.87872 | 1.91101 | 6.94209 | 0.88962 |
| Financing Cash Flow Items | -0.01931 | 0.00227 | -0.05314 | -0.00197 | |
| Issuance (Retirement) of Stock, Net | 0.03067 | 4.24472 | 0.00001 | 8.30344 | 0.09625 |
| Issuance (Retirement) of Debt, Net | 1.10288 | -0.36827 | 1.96413 | -1.36135 | 0.79533 |
| Net Change in Cash | -4.39391 | 3.23553 | 0.65664 | 3.77224 | -1.27776 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -2.31505 | -2.49381 | -0.82594 | 0.05152 | 0.73567 |
| Cash From Operating Activities | -2.76199 | -1.54387 | -0.24605 | 1.01199 | 0.63854 |
| Cash From Operating Activities | 0.65213 | 2.46848 | 1.869 | 1.24146 | 0.61685 |
| Amortization | 0.00478 | 0.0191 | 0.01433 | 0.00955 | 0.00478 |
| Deferred Taxes | |||||
| Non-Cash Items | 0.11487 | 0.29504 | 0.2016 | 0.11255 | 0.04908 |
| Cash Interest Paid | 0.08804 | 0.33852 | 0.2473 | 0.1594 | 0.07188 |
| Changes in Working Capital | -1.21872 | -1.83269 | -1.50503 | -0.40309 | -0.76783 |
| Cash From Investing Activities | -0.68215 | -3.96427 | -2.4741 | -1.73979 | -0.7965 |
| Capital Expenditures | -0.68217 | -3.97527 | -2.4851 | -1.75079 | -0.8075 |
| Other Investing Cash Flow Items, Total | 0.00002 | 0.011 | 0.011 | 0.011 | 0.011 |
| Cash From Financing Activities | 0.74862 | 1.11424 | 1.36245 | 1.58555 | 1.78963 |
| Financing Cash Flow Items | 0 | -0.01931 | -0.01931 | -0.01931 | -0.01883 |
| Issuance (Retirement) of Stock, Net | 0 | 0.03067 | 0.03067 | 0.03067 | 0.00584 |
| Issuance (Retirement) of Debt, Net | 0.74862 | 1.10288 | 1.35108 | 1.57418 | 1.80262 |
| Net Change in Cash | -2.69551 | -4.39391 | -1.3577 | 0.85776 | 1.63167 |
| Cash Taxes Paid | 0.00721 | 0.00492 | 0.00458 | 0.00458 | 0.00554 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Pessin (Norman H) | Individual Investor | 8.3133 | 644019 | -59617 | 2023-04-14 | LOW |
| Rothschild (Jonathan E) | Individual Investor | 6.635 | 514003 | 0 | 2023-04-14 | LOW |
| Pessin (Sandra F) | Individual Investor | 5.1869 | 401819 | 0 | 2023-04-14 | LOW |
| Brigham (Michael F) | Individual Investor | 2.785 | 215752 | 0 | 2023-04-14 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6633 | 206325 | 0 | 2023-06-30 | LOW |
| Crabb (Joseph H) | Individual Investor | 1.8439 | 142845 | 0 | 2023-04-14 | LOW |
| Pessin (Brian L) | Individual Investor | 1.7669 | 136882 | 26200 | 2023-04-14 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.5799 | 122389 | -438 | 2023-06-30 | HIGH |
| Tomsche (David Scott) | Individual Investor | 1.3374 | 103606 | 3100 | 2023-09-06 | LOW |
| Bleichroeder LP | Investment Advisor | 1.3114 | 101594 | 0 | 2023-06-30 | LOW |
| Cresset Asset Management, LLC | Investment Advisor/Hedge Fund | 1.2974 | 100506 | 0 | 2023-06-30 | HIGH |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.9678 | 74974 | 3600 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.8295 | 64264 | -425 | 2023-06-30 | LOW |
| Shufro, Rose & Co., LLC | Investment Advisor | 0.8056 | 62408 | 0 | 2023-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5903 | 45727 | 7645 | 2023-06-30 | LOW |
| Empire Financial Management Company, LLC | Investment Advisor | 0.5422 | 42000 | 0 | 2023-06-30 | LOW |
| Overbrook Management Corporation | Investment Advisor | 0.4241 | 32857 | 0 | 2023-06-30 | |
| Strategic Financial Services, Inc. | Investment Advisor | 0.4002 | 31000 | 0 | 2023-06-30 | LOW |
| Perritt Capital Management, Inc. | Investment Advisor | 0.3489 | 27026 | -2649 | 2023-06-30 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.2756 | 21354 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
ImmuCell Company profile
About ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ImmuCell Corporation revenues increased 19% to $13.8M. Net loss decreased 87% to $152K. Revenues reflect First Defense® product line segment increase of 44% to $9.5M, Other animal health segment increase of 83% to $186K, United States segment increase of 18% to $12.2M, Others segment increase of 28% to $1.6M.
Equity composition
Common Stock $.10 Par, 12/10, 8M auth., 3,261,148 issd., less 287,496 shs. in Treas. @ $635K. Insiders own 26.70%. PO 5/87, 966,000 Units (100 Common + 5 Warrants) @ $7/Unit by Stuart James. 7/90, 1-for-100 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
56 Evergreen Drive
PORTLAND
MAINE 04103
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com